ImetelChat

Thanks. Appreciate the detail response. And, I did not recognize your identity on ST.

The specific pathway of this enzyme.....are there any other compounds in development by other companies that strive to achieve the same effect of telomere manipulation? Understand the patent restrictions owned by the company. But I imagine, ( and that is the question, really), that, somewhere, some ...

Irrespective of the results, the drug, it's pathway is unique. Certainly would seem like an extreme bargain buy right now. 4 or 5 a share would probably do it.

FWIW: IMO.....Ultimately I believe that it was for these very reasons that JnJ decided to withdraw. The "Billion dollar pipeline: that they touted at their press conferences regarding the potential revenue stream for Imetestat, was, apparently, grossly miscalculated. And the "competing" trials, dire...

Thanks for the great read, insights and educated "guessing".
I've held this stock for what seems like ages.
During all that time the company has never look so "on track" as it does now.
Couple more years..................!!

GLTA

Thanks BP.

One of you folks help me understand the numbers... 57 locations, with 170 participants total?. That seems to equate to 3+ patients per location trial????

Finally....lol

Much appreciated BP.

With such a devoted and savvy membership here, it seems somehow disrespectful to even mention money. So pardon me for saying so, however this stock is, and always has been, a terrible investment. In the world of biotechs it is a well known fact that the bulk are a mean gamble at best. This one, afte...

Thank you for your devotion and excellent summary of your take, and interactions, at the meeting!! Kudos!

Share price and such are never a topic here. Perhaps rightfully so. Suffice it to say that it is NOT a good time for the lowly investor in this co. And I do not see that changing any time soon.

The extended time frames are disappointing. But the idea of a sit down with the FDA and trying an end run around needing a dual trial for MF given the current stats, is a novel idea worth pursuing. Kudos for the crew that came up with it

At some point in this progression it seems as though the left hand has no idea of what the right hand is doing. Rhetorical question is why is there such a disconnect between the stats offered by the sub-group of 13, and the FDA's apparent indifference to the same? OS is the standard. As it should be...

And this CT filing adds to the mystery.

Was said that it would take a full year to return all data. Dated from the 9/28 CD, that puts full return in the Fall. Would/could Geron open a P3 without that data secured and analyzed? Seems the $$ burn rate, if extended until sometime in the Fall, would necessitate the share offering sooner rathe...

My apology. You are correct. Fast track, no. Orphan status, yes.
Blinded by wishful thinking, I suppose.

EMA granted fast track to IMET in '15..... IMO approval for MF will come from them before the FDA.

Have to give him some kudos for his choices here and w/ Rizo etc. The CRO and the Dr. are top of the line. Redemption is full his if he can pull this off.

Without a major firms marketing, sales force, contacts and it's own reputation, approval of this drug is, in and of itself, not a blanket guarantee that it will have a commercial success. One of the downsides of the loss of the JnJ partnership. Going it alone, through the P3, and beyond ....to the m...